Skip to main content

Table 4 The most enrichment pathways related to tumorgegesis by KEGG

From: Folic Acid supplementary reduce the incidence of adenocarcinoma in a mouse model of colorectal cancer: microarray gene expression profile

Pathway ID Pathway name Selection Count Count Enrichment
mmu05219 Bladder cancer - Mus musculus (mouse) 22 44 3.709033
mmu05216 Thyroid cancer - Mus musculus (mouse) 17 31 3.597993
mmu03430 Mismatch repair - Mus musculus (mouse) 13 23 3.030142
mmu05211 Renal cell carcinoma - Mus musculus (mouse) 30 77 2.524291
mmu04520 Adherens junction - Mus musculus (mouse) 29 79 2.035831
mmu04912 GnRH signaling pathway - Mus musculus (mouse) 36 104 1.939698
mmu05214 Glioma - Mus musculus (mouse) 27 74 1.892937
mmu04110 Cell cycle - Mus musculus (mouse) 46 140 1.872654
mmu05215 Prostate cancer - Mus musculus (mouse) 31 94 1.446692
mmu04150 mTOR signaling pathway - Mus musculus (mouse) 20 56 1.429803
mmu05200 Pathways in cancer - Mus musculus (mouse) 98 345 1.369825
mmu05221 Acute myeloid leukemia - Mus musculus (mouse) 21 61 1.309804
  1. "SelectionCounts" stands for the Count of the DE genes' entities directly associated with the listed PathwayID;
  2. "Count" stands for the count of the chosen background population genes' entities associated with the listed PathwayID;